GIPR and type 2 diabetes mellitus: Recently, the gastric inhibitory polypeptide receptor/GLP1R (GIPR/GLP1R) co-agonist, tirzepatide, became the first polyagonist approved for the treatment of T2DM; it induces a staggering 22% average weight loss in patients with obesity (1).